Oneness Biotech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Oneness Biotech şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-0.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.1%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	NT$0.0824
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 4743 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 4743 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Oneness Biotech Piyasaya Karşı Temettü Getirisi

4743 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (4743)	0%
Pazarın Alt %25'i (TW)	1.7%
Pazarın En İyi %25'i (TW)	4.5%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (4743) (3 yıla kadar)	0%

Önemli Temettü: 4743 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 4743 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 4743 TW piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 4743 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Oneness Biotech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Oneness Biotech Co., Ltd. has filed a Follow-on Equity Offering.

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Price target decreased by 14% to NT$262

Consensus revenue estimates increase by 158%

Oneness Biotech Co., Ltd. Announces Approval of FESPIXON

New minor risk - Share price stability

New minor risk - Shareholder dilution

Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis

New minor risk - Revenue size

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Price target decreased by 10% to NT$274

Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan (DRAP)

US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai)

Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Third quarter 2022 earnings released

Third quarter 2022 earnings released: EPS: NT$0.71 (vs NT$0.46 loss in 3Q 2021)

Microbio (Shanghai) and Oneness Co-Develop Broad-Spectrum siRNA (SNS812) to Treat SARS-CoV-2 Infection, Greenlighted by FDA to Proceed with A Phase I Study

Oneness Biotech Co., Ltd. Submits an IND to US FDA for A Phase Iclinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA (SNS812) Co-Developed with Microbio (Shanghai)

Second quarter 2022 earnings released: EPS: NT$0.87 (vs NT$1.24 loss in 2Q 2021)

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

First quarter 2022 earnings released: EPS: NT$1.01 (vs NT$0.31 in 1Q 2021)

Oneness Biotech Co., Ltd. Announces Food and Drug Administration Philippines Accepts NDA Application of Diabetic Foot Ulcer New Drug, Fespixon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oneness Biotech Co., Ltd. Announces The Malaysia National Pharmaceutical Regulatory Agency Accepts NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd. Announces the Data of Sns812 Were Published by EMBO Molecular Medicine

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

Third quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.064 profit in 3Q 2020)

Independent Director Kun-Ta Li has left the company

Second quarter 2021 earnings released: NT$1.24 loss per share (vs NT$1.40 profit in 2Q 2020)

Oneness Biotech Co., Ltd. Announces Phase 3 International MRCT Study Results of the Diabetic Foot Ulcer New Drug

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

Oneness Notified That FB704A Is Safe to Proceed with the Phase 2 Clinical Trial in Severe Asthma Under US FDA IND

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Full year 2020 earnings released: NT$0.68 loss per share (vs NT$1.28 loss in FY 2019)

Oneness Biotech Co., Ltd. Receives the Letter from MOHW Informing that ON101 for DFUs has Obtained the New Drug Approval Andits Drug Certificate Will Be Notified for Receipt

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Oneness Submits an IND to US FDA on Phase II Clinical Trial on Severe Asthma of FB704A

Oneness Will Not Proceed with the ON101 Phase3 Clinical Trial (ON101CLCT04) Application with BfArM of Germany Based on Strategic Consideration

New 90-day low: NT$185

New 90-day low: NT$213

TFDA Notifies Oneness of Submitting Supplementary information for Rebuttal of FB704A Phase II Clinical trial Application for Severe Neutrophilic Asthma

New 90-day low: NT$260

Third quarter 2020 earnings released: EPS NT$0.06

New 90-day low: NT$265

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin